董玲①, 孟斌②, 张新伟③, 宋秀宇④, 张希梅⑤, 翟琼莉②, 刘霞①, 侯芸①, 李维①, 王先火①, 王华庆⑥, 付凯⑦, 张会来①. ALK+弥漫大B 细胞淋巴瘤患者临床决策探讨*[J]. 中国肿瘤临床, 2016, 43(9): 385-391. DOI: 10.3969/j.issn.1000-8179.2016.09.350
引用本文: 董玲①, 孟斌②, 张新伟③, 宋秀宇④, 张希梅⑤, 翟琼莉②, 刘霞①, 侯芸①, 李维①, 王先火①, 王华庆⑥, 付凯⑦, 张会来①. ALK+弥漫大B 细胞淋巴瘤患者临床决策探讨*[J]. 中国肿瘤临床, 2016, 43(9): 385-391. DOI: 10.3969/j.issn.1000-8179.2016.09.350
Ling DONG1, Bin MENG2, Xinwei ZHANG3, Xiuyu SONG4, Ximei ZHANG5, Qiongli ZHAI2, Xia LIU1, Yun HOU1, Wei LI1, Xianhuo WANG1, Huaq-ing WANG6, Kai FU7, Huilai ZHANG1. Clinical decision on a patient with ALK+ diffuse large B cell lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(9): 385-391. DOI: 10.3969/j.issn.1000-8179.2016.09.350
Citation: Ling DONG1, Bin MENG2, Xinwei ZHANG3, Xiuyu SONG4, Ximei ZHANG5, Qiongli ZHAI2, Xia LIU1, Yun HOU1, Wei LI1, Xianhuo WANG1, Huaq-ing WANG6, Kai FU7, Huilai ZHANG1. Clinical decision on a patient with ALK+ diffuse large B cell lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 43(9): 385-391. DOI: 10.3969/j.issn.1000-8179.2016.09.350

ALK+弥漫大B 细胞淋巴瘤患者临床决策探讨*

Clinical decision on a patient with ALK+ diffuse large B cell lymphoma

  • 摘要: ALK+弥漫大B 细胞淋巴瘤(anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma ,ALK+DLBCL )是淋巴瘤中一种罕见的和具有明显差异性的病理类型,2008年WHO将其归类为DLBCL 一个独特的亚型,该病侵袭性高,容易复发,目前尚无规范有效的治疗方案。采取多学科协作体系(multidisciplinary treatment ,MDT )有利于制定规范化、个体化的治疗方案,探索针对ALK+DLBCL 患者更有效的治疗方法,从而让更多的患者获益。本研究分享1 例2012年1 月天津医科大学肿瘤医院收治的ALK+DLBCL 高剂量化疗联合自体造血干细胞移植(autologous hematopoietic stem cell transplantation ,AHSCT)后复发,采用ALK 激酶抑制剂克唑替尼(Crizotinib )治疗成功的案例。

     

    Abstract: Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008WHO classification of lymphomas. No standard and effective therapeutic regi -men is available for ALK +DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This arti -cle presents a case of an ALK+ DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibi-tor Crizotinib.

     

/

返回文章
返回